Procter & Gamble Health Limited (PGHL.BO)
INR 5104.95
(-0.72%)
INR 5104.95
(-0.72%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 2.78 Billion INR | -7.53% |
| 2022 | 3.01 Billion INR | 23.39% |
| 2021 | 2.44 Billion INR | 9.39% |
| 2020 | 2.23 Billion INR | 13.4% |
| 2019 | 1.96 Billion INR | 53.51% |
| 2018 | 1.28 Billion INR | 66.92% |
| 2017 | 768.2 Million INR | -23.97% |
| 2016 | 1.01 Billion INR | 62.94% |
| 2015 | 620.1 Million INR | 32.25% |
| 2014 | 468.9 Million INR | -32.26% |
| 2013 | 692.2 Million INR | -29.13% |
| 2012 | 976.7 Million INR | 30.28% |
| 2011 | 749.7 Million INR | -31.88% |
| 2010 | 1.1 Billion INR | 14.08% |
| 2009 | 964.8 Million INR | 5.16% |
| 2008 | 917.5 Million INR | -8.13% |
| 2007 | 998.7 Million INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 1.08 Billion INR | 163.49% |
| 2023 FY | 2.78 Billion INR | -7.53% |
| 2023 Q4 | 410.9 Million INR | -34.97% |
| 2023 Q3 | 631.9 Million INR | -33.29% |
| 2023 Q2 | 947.3 Million INR | 15.27% |
| 2023 Q1 | 821.8 Million INR | 111.59% |
| 2022 Q4 | 388.4 Million INR | -47.35% |
| 2022 FY | 3.01 Billion INR | 23.39% |
| 2022 Q3 | 737.7 Million INR | -26.69% |
| 2022 Q2 | 1 Billion INR | 20.75% |
| 2022 Q1 | 833.4 Million INR | 59.35% |
| 2021 Q1 | 711.7 Million INR | 72.41% |
| 2021 Q3 | 626.5 Million INR | 13.39% |
| 2021 Q4 | 523 Million INR | -16.52% |
| 2021 Q2 | 552.5 Million INR | -22.37% |
| 2021 FY | 2.44 Billion INR | 9.39% |
| 2020 Q3 | 230.6 Million INR | -73.38% |
| 2020 Q2 | 866.2 Million INR | 11.83% |
| 2020 FY | 2.23 Billion INR | 13.4% |
| 2020 Q1 | 774.6 Million INR | 71.97% |
| 2020 Q4 | 412.8 Million INR | 79.01% |
| 2019 FY | 1.96 Billion INR | 53.51% |
| 2019 Q3 | 545.01 Million INR | 0.0% |
| 2019 Q1 | 458.51 Million INR | -8.34% |
| 2019 Q4 | 450.44 Million INR | -17.35% |
| 2018 Q2 | 107.15 Million INR | -80.11% |
| 2018 FY | 1.28 Billion INR | 66.92% |
| 2018 Q4 | 500.22 Million INR | 9.21% |
| 2018 Q3 | 458.03 Million INR | 327.47% |
| 2018 Q1 | 538.74 Million INR | 21.32% |
| 2017 FY | 768.2 Million INR | -23.97% |
| 2017 Q4 | 444.08 Million INR | 347.26% |
| 2017 Q3 | 99.29 Million INR | -39.73% |
| 2017 Q2 | 164.74 Million INR | -49.06% |
| 2017 Q1 | 323.38 Million INR | 212.87% |
| 2016 Q1 | 403.17 Million INR | 45.39% |
| 2016 FY | 1.01 Billion INR | 62.94% |
| 2016 Q4 | 103.36 Million INR | -55.18% |
| 2016 Q3 | 230.61 Million INR | -33.41% |
| 2016 Q2 | 346.33 Million INR | -14.1% |
| 2015 Q4 | 277.3 Million INR | 163.5% |
| 2015 Q1 | 201.79 Million INR | -23.17% |
| 2015 Q2 | 234.35 Million INR | 16.14% |
| 2015 Q3 | 105.23 Million INR | -55.1% |
| 2015 FY | 620.1 Million INR | 32.25% |
| 2014 Q1 | 265.36 Million INR | -16.11% |
| 2014 Q4 | 262.66 Million INR | 95.33% |
| 2014 Q3 | 134.47 Million INR | 177.74% |
| 2014 FY | 468.9 Million INR | -32.26% |
| 2014 Q2 | -172.98 Million INR | -165.19% |
| 2013 Q2 | -13.21 Million INR | -105.41% |
| 2013 Q3 | 60.2 Million INR | 555.51% |
| 2013 Q4 | 316.31 Million INR | 425.45% |
| 2013 FY | 692.2 Million INR | -29.13% |
| 2013 Q1 | 244.46 Million INR | -4.16% |
| 2012 Q1 | 389.25 Million INR | 27.58% |
| 2012 Q4 | 255.06 Million INR | 23.89% |
| 2012 Q3 | 205.88 Million INR | -53.81% |
| 2012 FY | 976.7 Million INR | 30.28% |
| 2012 Q2 | 445.74 Million INR | 14.51% |
| 2011 Q3 | 142.5 Million INR | -66.54% |
| 2011 Q1 | 261.96 Million INR | 0.0% |
| 2011 FY | 749.7 Million INR | -31.88% |
| 2011 Q4 | 305.1 Million INR | 114.1% |
| 2011 Q2 | 425.9 Million INR | 62.58% |
| 2010 FY | 1.1 Billion INR | 14.08% |
| 2009 FY | 964.8 Million INR | 5.16% |
| 2008 FY | 917.5 Million INR | -8.13% |
| 2007 FY | 998.7 Million INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 5.75 Billion INR | 51.616% |
| Aurobindo Pharma Limited | 42.2 Billion INR | 93.399% |
| Glenmark Life Sciences Limited | 8.97 Billion INR | 68.973% |
| Granules India Limited | 6.81 Billion INR | 59.13% |
| Indoco Remedies Limited | 1.29 Billion INR | -115.543% |
| Achyut Healthcare Limited | 4.43 Million INR | -62676.025% |
| Ajanta Pharma Limited | 19.67 Billion INR | 85.842% |
| Alkem Laboratories Limited | 19.46 Billion INR | 85.685% |
| Alpa Laboratories Limited | 184.49 Million INR | -1410.052% |
| Brooks Laboratories Limited | 14.44 Million INR | -19193.629% |
| AstraZeneca Pharma India Limited | 1.71 Billion INR | -62.213% |
| Bajaj HealthCare Limited | - INR | -Infinity% |
| Bliss GVS Pharma Limited | 1.23 Billion INR | -126.32% |
| Dr. Reddy's Laboratories Limited | 67.72 Billion INR | 95.887% |
| Eris Lifesciences Limited | 5.18 Billion INR | 46.234% |
| FDC Limited | 2.98 Billion INR | 6.704% |
| Glenmark Pharmaceuticals Limited | 6.5 Billion INR | 57.154% |
| Gufic Biosciences Limited | 1.32 Billion INR | -109.488% |
| Ind-Swift Laboratories Limited | 4.42 Billion INR | 36.976% |
| Ipca Laboratories Limited | 7.98 Billion INR | 65.09% |
| Jagsonpal Pharmaceuticals Limited | 508.13 Million INR | -448.285% |
| Krebs Biochemicals & Industries Limited | -151.95 Million INR | 1933.413% |
| Lasa Supergenerics Limited | -458 Million INR | 708.29% |
| Laurus Labs Limited | 3.94 Billion INR | 29.443% |
| Lupin Limited | 28.04 Billion INR | 90.066% |
| Mankind Pharma Limited | 21.51 Billion INR | 87.053% |
| Medicamen Biotech Limited | - INR | -Infinity% |
| Medico Remedies Limited | 100.3 Million INR | -2677.667% |
| Megasoft Limited | -121.1 Million INR | 2400.502% |
| NATCO Pharma Limited | 25.96 Billion INR | 89.269% |
| Piramal Pharma Limited | 4.55 Billion INR | 38.862% |
| RPG Life Sciences Limited | 2.29 Billion INR | -21.537% |
| Sigachi Industries Limited | 1.47 Billion INR | -89.023% |
| Sun Pharmaceutical Industries Limited | 104.3 Billion INR | 97.329% |
| Suven Pharmaceuticals Limited | 4.6 Billion INR | 39.535% |
| Syncom Formulations (India) Limited | 249.25 Million INR | -1017.749% |
| Unichem Laboratories Limited | - INR | -Infinity% |
| Wanbury Limited | 569.71 Million INR | -389.016% |
| Windlas Biotech Limited | 1.29 Billion INR | -114.491% |
| ZIM Laboratories Limited | 253.82 Million INR | -997.589% |
| Zydus Lifesciences Limited | 43.1 Billion INR | 93.537% |
| Sun Pharma Advanced Research Company Limited | -4.11 Billion INR | 167.703% |
| Divi's Laboratories Limited | 33.08 Billion INR | 91.578% |
| Hester Biosciences Limited | 364.81 Million INR | -663.685% |
| Amrutanjan Health Care Limited | 457.54 Million INR | -508.903% |
| Bal Pharma Limited | 233.9 Million INR | -1091.061% |
| Strides Pharma Science Limited | 5.22 Billion INR | 46.688% |
| Venus Remedies Limited | 534.65 Million INR | -421.088% |
| Aarti Pharmalabs Limited | 3.12 Billion INR | 10.937% |
| Nectar Lifesciences Limited | 923.8 Million INR | -201.578% |
| Shilpa Medicare Limited | 1.36 Billion INR | -103.913% |
| Aarti Drugs Limited | 7.14 Billion INR | 61.028% |
| IOL Chemicals and Pharmaceuticals Limited | 1.59 Billion INR | -74.474% |
| Suven Life Sciences Limited | -1.22 Billion INR | 327.276% |
| Ind-Swift Limited | 1.22 Billion INR | -127.25% |
| Valiant Laboratories Limited | - INR | -Infinity% |
| J. B. Chemicals & Pharmaceuticals Limited | 14.28 Billion INR | 80.494% |
| Solara Active Pharma Sciences Limited | -3.85 Billion INR | 172.309% |
| Themis Medicare Limited | 392.58 Million INR | -609.648% |
| Hikal Limited | 32.11 Million INR | -8576.425% |
| Torrent Pharmaceuticals Limited | 25.33 Billion INR | 89.003% |
| Sequent Scientific Limited | - INR | -Infinity% |
| Novartis India Limited | 626.5 Million INR | -344.693% |
| Wockhardt Limited | -670 Million INR | 515.821% |
| Jubilant Pharmova Limited | 5.18 Billion INR | 46.31% |
| Biofil Chemicals and Pharmaceuticals Limited | 9.06 Million INR | -30621.052% |
| Neuland Laboratories Limited | 5.31 Billion INR | 47.613% |
| Morepen Laboratories Limited | 4.17 Billion INR | 33.251% |
| Kilitch Drugs (India) Limited | 208.05 Million INR | -1239.101% |
| Mangalam Drugs & Organics Limited | 27.45 Million INR | -10046.405% |